Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$1.75 +1.2%	$2.29	$1.11 ▼ $5.00	$465.75M	1.9	1.89 million shs	2.22 million shs
AVTX Avalo Therapeutics	$9.37 +1.6%	$6.42	$3.39 ▼ $16.00	$123.22M	0.8	115,384 shs	102,324 shs
ERAS Erasca	$1.50 +2.7%	$1.48	$1.01 ▼ $3.31	$425.51M	1.07	1.38 million shs	1.36 million shs
PRME Prime Medicine	$3.22 -0.6%	$3.46	$1.11 ▼ $5.17	$433.33M	2.39	2.53 million shs	1.79 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	-3.35%	-5.98%	-28.81%	+13.07%	-56.64%
AVTX Avalo Therapeutics	+3.60%	+1.65%	+37.00%	+135.81%	+3.48%
ERAS Erasca	-3.95%	-9.88%	-2.67%	+20.66%	-47.29%
PRME Prime Medicine	0.00%	-14.96%	-29.10%	+163.41%	-25.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	3.0469 of 5 stars	3.5	1.0	3.8	3.3	0.6
AVTX Avalo Therapeutics	3.3239 of 5 stars	3.5	5.0	2.6	1.7	0.6
ERAS Erasca	2.1527 of 5 stars	3.4	1.0	1.6	2.5	0.6
PRME Prime Medicine	2.8561 of 5 stars	3.4	1.0	1.8	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.12	419.66% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	219.83% Upside
ERAS Erasca	2.86	Moderate Buy	$4.29	185.71% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	176.49% Upside

Current Analyst Ratings Breakdown

Latest AVTX, AUTL, PRME, and ERAS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ERAS Erasca	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00 ➝ $2.00
8/15/2025	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	46.15	N/A	N/A	$1.30 per share	1.35
AVTX Avalo Therapeutics	$440K	280.33	N/A	N/A	$7.95 per share	1.18
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
PRME Prime Medicine	$4.96M	87.48	N/A	N/A	$1.37 per share	2.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	N/A
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	-48.48%	-35.94%	11/6/2025 (Estimated)
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest AVTX, AUTL, PRME, and ERAS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/7/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	-$1.92	-$0.49	-$1.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	44.84%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	8.43	8.07
AVTX Avalo Therapeutics	N/A	12.44	12.44
ERAS Erasca	N/A	11.03	11.04
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
AVTX Avalo Therapeutics	87.06%
ERAS Erasca	67.78%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
AVTX Avalo Therapeutics	3.03%
ERAS Erasca	14.40%
PRME Prime Medicine	22.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
AVTX Avalo Therapeutics	40	13.15 million	12.75 million	Not Optionable
ERAS Erasca	120	283.67 million	242.82 million	Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable

AVTX, AUTL, PRME, and ERAS Headlines

Recent News About These Companies

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $8.92

August 21 at 2:18 AM | americanbankingnews.com

Positive Signs As Multiple Insiders Buy Prime Medicine Stock

August 20 at 7:34 AM | uk.finance.yahoo.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Analysts

August 19 at 3:50 AM | marketbeat.com

Analysts Set Expectations for Prime Medicine FY2025 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

August 16, 2025 | marketbeat.com

HC Wainwright Cuts Earnings Estimates for Prime Medicine

August 16, 2025 | americanbankingnews.com

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00

August 10, 2025 | marketbeat.com

Prime Medicine (NYSE:PRME) Price Target Cut to $10.00 by Analysts at Chardan Capital

August 10, 2025 | americanbankingnews.com

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

August 8, 2025 | tipranks.com

PRME Revenue Misses by 73%

August 8, 2025 | aol.comA

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What Happened

August 6, 2025 | marketbeat.com

Prime Medicine Holds Special Stockholder Meeting

August 5, 2025 | tipranks.com

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

August 5, 2025 | marketbeat.com

Friday’s Insider Trades: Key Buys and Sells in US Stocks Revealed

August 4, 2025 | investing.com

Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) Stock

August 2, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares

August 2, 2025 | insidertrades.com

Prime Medicine Halts Sales Agreement Prospectus

August 1, 2025 | theglobeandmail.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

August 1, 2025 | finance.yahoo.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

August 1, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTX, AUTL, PRME, and ERAS Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$1.75 +0.02 (+1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$1.74 -0.01 (-0.57%)

As of 07:30 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Avalo Therapeutics NASDAQ:AVTX

$9.37 +0.15 (+1.63%)

Closing price 04:00 PM Eastern

Extended Trading

$9.38 +0.01 (+0.05%)

As of 04:10 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Erasca NASDAQ:ERAS

$1.50 +0.04 (+2.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 0.00 (-0.33%)

As of 05:24 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Prime Medicine NYSE:PRME

$3.22 -0.02 (-0.62%)

Closing price 04:00 PM Eastern

Extended Trading

$3.22 +0.00 (+0.16%)

As of 07:29 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time